The growing role of biologics and biosimilars in Greece
Patient access to safe and cost-effective treatments is an important goal for the health care system. As the availability and use of biosimilars, including those determined to be interchangeable, increases, their potential to lower costs and improve patient access to treatment grows. However, the extent of such growth is, in part, dependent on various stakeholders’ decisions to provide, pay for, or use these products in a safe and thoughtful manner. Ongoing stakeholder collaboration, educational activities, and review of current government or payer policies are required to optimize the uptake of biological products, including biosimilars.
Participation fees with Early Bird Until 27 August
Individual participation: 250€ + 24% VAT |
4 Company registrations (3+1 free): 750€ + 24% VAT |
8 Company registrations (6+2 free): 1500€ + 24% VAT |
Participation fees after 27 August
Individual participation: 300€ + 24% VAT |
4 Company registrations (3+1 free): 900€ + 24% VAT |
8 Company registrations (6+2 free): 1800€ + 24% VAT |
Πότε;
Τρίτη, 24 Σεπτεμβρίου 2019 9:00 πμΠού;
Divani Caravel Hotel, Macedonia HallΛεωφόρος Βασιλέως Αλεξάνδρου 2
161 21 Αθήνα
Κεντρικός Τομέας Αθηνών,Ελλάδα
Προβολή μεγαλύτερου χάρτη